Switching Within the Class of IL-17 Inhibitors for the Treatment of Plaque Psoriasis: A Real-world Retrospective Study

Overview

Journal Australas J Dermatol

Specialty Dermatology

Date 2024 Dec 12

PMID 39665153

Authors

Ioannis-Alexios Koumprentziotis

Natalia Rompoti

Irene Stefanaki

Charitomeni Vavouli

Marina Papoutsaki

Maria Politou

Alexander Stratigos

Electra Nicolaidou

Affiliations

Soon will be listed here.

Citing Articles

Switching within the class of IL-17 inhibitors for the treatment of plaque psoriasis: A real-world retrospective study.

Koumprentziotis I, Rompoti N, Stefanaki I, Vavouli C, Papoutsaki M, Politou M Australas J Dermatol. 2024; 66(2):101-104.

PMID: 39665153 PMC: 11898172. DOI: 10.1111/ajd.14396.

References

Sotiriou E, Bakirtzi K, Papadimitriou I, Tsentemeidou A, Kougkas N, Panagopoulou A . Real-life intraclass switch among IL-17 inhibitors in psoriasis: results from a single-centre, 24-week, retrospective study. J Eur Acad Dermatol Venereol. 2022; 36(11):e952-e953. DOI: 10.1111/jdv.18381. View

Hu Y, Chen Z, Gong Y, Shi Y . A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis. Clin Drug Investig. 2017; 38(3):191-199. DOI: 10.1007/s40261-017-0603-3. View

Mastorino L, Dapavo P, Burzi L, Rosset F, Giunipero di Corteranzo I, Leo F . Drug survival, effectiveness and safety of ixekizumab for moderate-to-severe psoriasis up to 5 years. J Eur Acad Dermatol Venereol. 2023; 38(3):568-575. DOI: 10.1111/jdv.19682. View

Georgakopoulos J, Phung M, Ighani A, Lam K, Yeung J . Biologic switching between interleukin 17A antagonists secukinumab and ixekizumab: a 12-week, multicenter, retrospective study. J Eur Acad Dermatol Venereol. 2018; 33(1):e7-e8. DOI: 10.1111/jdv.15100. View

Rompoti N, Sidiropoulou P, Panagakis P, Stratigos A, Papoutsaki M, Stefanaki E . Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response. J Eur Acad Dermatol Venereol. 2020; 34(6):1240-1247. DOI: 10.1111/jdv.16202. View

Tichy M, Kojanova M, Velackova B, Dolezal T, Gkalpakiotis S, Cetkovska P . Efficacy of switches within the class of IL-17 inhibitors: An analysis of data from the Czech nationwide registry of psoriatic patients receiving biological/targeted therapy (BIOREP). Dermatol Ther. 2022; 35(10):e15772. DOI: 10.1111/dth.15772. View

Rompoti N, Politou M, Stefanaki I, Vavouli C, Papoutsaki M, Neofotistou A . Brodalumab in plaque psoriasis: Real-world data on effectiveness, safety and clinical predictive factors of initial response and drug survival over a period of 104 weeks. J Eur Acad Dermatol Venereol. 2022; 37(4):689-697. DOI: 10.1111/jdv.18825. View

Loft N, Halling A, Egeberg A, Skov L . Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: A systematic review and meta-analysis. J Am Acad Dermatol. 2020; 84(1):130-138. DOI: 10.1016/j.jaad.2020.07.085. View

Kokolakis G, Warren R, Strober B, Blauvelt A, Puig L, Morita A . Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. Br J Dermatol. 2023; 188(3):330-340. DOI: 10.1093/bjd/ljac089. View

10.

Koumprentziotis I, Rompoti N, Stefanaki I, Vavouli C, Papoutsaki M, Politou M . Switching within the class of IL-17 inhibitors for the treatment of plaque psoriasis: A real-world retrospective study. Australas J Dermatol. 2024; 66(2):101-104. PMC: 11898172. DOI: 10.1111/ajd.14396. View

11.

Gasslitter I, Kirsten N, Augustin M, Torz K, Mrowietz U, Eyerich K . Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study. Arch Dermatol Res. 2019; 311(5):421-424. DOI: 10.1007/s00403-019-01907-y. View